The role of palbociclib in thyroid carcinoma with BRAF mutation

about

The role of palbociclib in thyroid carcinoma with BRAF mutation

Item

http://www.wikidata.org/entity/Q58805425

description

scientific article published on 01 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

The role of palbociclib in thyroid carcinoma with BRAF mutation

@en

The role of palbociclib in thyroid carcinoma with BRAF mutation

@nl

type

Item

label

The role of palbociclib in thyroid carcinoma with BRAF mutation

@en

The role of palbociclib in thyroid carcinoma with BRAF mutation

@nl

prefLabel

The role of palbociclib in thyroid carcinoma with BRAF mutation

@en

The role of palbociclib in thyroid carcinoma with BRAF mutation

@nl

P1476

The role of palbociclib in thyroid carcinoma with BRAF mutation

@en

P2093

Konstantinos Tsapakidis

http://www.w3.org/2001/XMLSchema#string

Nikolaos Tsoukalas

http://www.w3.org/2001/XMLSchema#string

P2860

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

Progress in molecular-based management of differentiated thyroid cancer

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.

Resistance to Raf inhibition in cancer.

Molecular pathogenesis and mechanisms of thyroid cancer

P304

S82-S85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/GS.2018.03.07

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Krystallenia I Alexandraki

P577

2018-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30175070

http://www.w3.org/2001/XMLSchema#string

P932

6107606

http://www.w3.org/2001/XMLSchema#string